文献速递重症综合管理与镇静镇痛心脑血管急症

血浆淀粉样蛋白β1-40与心脏手术后谵妄

Plasma Amyloid-β 1-40 and Postoperative Delirium After Cardiac Surgery.
PubMed 文献 · JAMA Netw Open · 2026-07-01
一句话结论择期心脏手术患者术前血浆Aβ1-40与术后谵妄独立相关,联合临床因素及MoCA可提升风险估计,但尚需验证临床实用性。

该前瞻性观察队列(FINDERI)纳入德国单中心504例≥50岁择期心脏手术患者,491例完成术后5天CAM评估,106例(21.6%)发生术后谵妄。术前血浆Aβ1-40是与POD关联最强的独立生物标志物(AUC 0.65)。生物标志物联合临床因素AUC 0.74,再加MoCA达0.77。提示术前Aβ1-40可能有助于POD风险分层,但临床效用待验证。

要点

  • 择期心脏手术患者术前血浆Aβ1-40升高与术后谵妄风险独立相关(AUC 0.65,95%CI 0.59-0.71)。
  • 生物标志物+临床因素模型AUC 0.74,加入MoCA后AUC 0.77,均高于临床因素单独(AUC 0.73)。
  • 发生POD者术前Aβ1-40、Aβ1-42、pTau217及Aβ1-40/Aβ1-42×pTau217更高,Aβ1-42/Aβ1-40更低。
  • pTau217与年龄均与较低MoCA评分独立相关(β分别为-0.51和-0.12)。
  • 该研究为单中心前瞻性观察队列,Aβ1-40的临床效用尚需进一步验证。

适用人群与场景

  • ≥50岁、在德国单中心接受择期心脏手术的患者(FINDERI队列,2021年2月至2022年10月入组)。
  • 排除标准原文未提及;原文未提及急诊或ICU场景的适用性。

诊断标准与关键阈值

  • 术后谵妄:术后5天内每日采用Confusion Assessment Method(CAM)算法评估。
  • 基线认知:Montreal Cognitive Assessment(MoCA)评估。
  • 术前血浆Aβ1-40、Aβ1-42、pTau181、pTau217采用经验证的免疫测定法检测。

处置流程与药物剂量

  • 原文未提及(无干预或治疗推荐,仅涉及术前生物标志物风险评估)。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:前瞻性观察队列(FINDERI),单中心,504例入组、491例完成POD评估,平均年龄68.4岁,78.4%男性。
  • 主要终点:106例(21.6%)发生POD;Aβ1-40为与POD关联最强的独立生物标志物,AUC 0.65(95%CI 0.59-0.71,P<.001)。
  • 生物标志物+临床因素模型AUC 0.74(95%CI 0.69-0.79),临床因素单独AUC 0.73(95%CI 0.67-0.78),两者P<.001。
  • 加入MoCA的联合模型AUC 0.77(95%CI 0.72-0.82,P<.001),主要由Aβ1-40驱动。
  • POD组术前Aβ1-40、Aβ1-42、pTau217及Aβ1-40/Aβ1-42×pTau217更高,Aβ1-42/Aβ1-40更低;pTau217(β=-0.51,95%CI -0.89至-0.12,P=.01)和年龄(β=-0.12,95%CI -0.16至-0.08,P<.001)与较低MoCA评分独立相关。

证据类型、等级与局限

  • 证据类型:前瞻性观察队列研究(单中心)。
  • 局限:单中心、观察性设计,AUC提升幅度有限,原文结论明确需进一步研究验证并确定临床效用。

对床旁实践的改变

  • 提示术前血浆Aβ1-40可能用于择期心脏手术患者POD风险分层,但原文强调尚需验证,不能据此作为床旁决策阈值。
  • 原文未提及对急诊或ICU其他人群的适用性,不适用于非心脏手术或非择期场景。

指南或共识出处

  • 原文未提及指南或共识;来源为JAMA Netw Open发表的FINDERI研究。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Postoperative delirium (POD) is a frequent and severe complication after cardiac surgery that is associated with increased risk of dementia and adverse outcomes. Early identification of high-risk patients remains challenging.

OBJECTIVE: To examine whether preoperative plasma Alzheimer disease biomarkers are associated with baseline cognition and can independently estimate POD in patients undergoing elective cardiac surgery.

DESIGN, SETTING, AND PARTICIPANTS: This prospective, observational cohort study (FIND Delirium Risk Factors [FINDERI]) included patients 50 years or older undergoing elective cardiac surgery at a comprehensive cardiac surgery center in Germany between February 1, 2021, and October 31, 2022. Statistical analysis was performed from January to December 2025.

EXPOSURES: Preoperative plasma concentrations of amyloid-β 1-40 (Aβ1-40), amyloid-β 42 (Aβ1-42), phosphorylated tau 181 (pTau181), and phosphorylated tau 217 (pTau217) were measured using validated immunoassays between November 1, 2022, and July 31, 2024.

MAIN OUTCOMES AND MEASURES: The primary outcome was POD, assessed daily for 5 days postoperatively using the Confusion Assessment Method algorithm. Baseline cognitive function was assessed using the Montreal Cognitive Assessment (MoCA). Risk estimation accuracy was evaluated using receiver operating characteristic analysis and multivariate logistic regression, adjusting for relevant clinical covariates.

RESULTS: Of 504 enrolled patients, 491 completed POD assessment (mean [SD] age, 68.4 [8.3] years; 385 [78.4%] male), of whom 106 (21.6%) developed POD. In multiple linear regression, pTau217 (β = -0.51; 95% CI, -0.89 to -0.12; P = .01) and age (β = -0.12; 95% CI, -0.16 to -0.08; P < .001) remained significant factors associated with lower MoCA scores. Patients who developed POD had higher preoperative Aβ1-40, Aβ1-42, pTau217, and Aβ1-40/Aβ1-42 × pTau217, and lower Aβ1-42/Aβ1-40. Aβ1-40 was the independent biomarker most strongly associated with POD (area under the receiver operating curve [AUC], 0.65; 95% CI, 0.59-0.71; P < .001). Combining biomarkers with clinical factors improved risk estimation (AUC, 0.74; 95% CI, 0.69-0.79; P < .001) compared with clinical factors alone (AUC, 0.73; 95% CI, 0.67-0.78; P < .001). A combined model including MoCA achieved an AUC of 0.77 (95% CI, 0.72-0.82; P < .001), driven primarily by Aβ1-40.

CONCLUSIONS AND RELEVANCE: In this prospective cohort study, preoperative Aβ1-40 showed the strongest association with POD risk among the measured biomarkers. These findings suggest that preoperative plasma Aβ1-40 may contribute to POD risk stratification, but further research is needed to validate these findings and determine clinical utility.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. von Arnim CAF, Sadlonova M, Derad C, et al. Plasma Amyloid-β 1-40 and Postoperative Delirium After Cardiac Surgery. JAMA Netw Open. 2026. PMID: 42518233. doi:10.1001/jamanetworkopen.2026.25730

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。